AI-enabled precision medicine

Tempus Refresh now available – automatic therapy updates that evolve with your patient | Learn more Tempus Refresh now available – automatic therapy updates that evolve with your patient |

AI-enabled
precision medicine

With the power of AI, we now have the ability to

  • ACCELERATE

    the discovery of novel targets

  • PREDICT

    the effectiveness of treatments

  • IDENTIFY

    potentially life-saving clinical trials

  • DIAGNOSE

    multiple diseases earlier

Discover our innovative technology

Explore our tech & AI
ONE
AI-enabled assistant for healthcare providers and researchers
NEXT
Identify and close gaps in care
LENS
Find, access, and analyze multimodal real-world data
ALGOS
Algorithmic models connected to our assays to provide additional insight
Explore our tech & AI
WATCH OUR STORY

Explore Tempus

PROVIDERS

We can help physicians make more informed treatment decisions.

Learn More
LIFE SCIENCES

We can assist pharmaceutical and biotech companies with better drug development.

Learn More
PATIENTS

We can help patients find their own unique and optimal therapy options.

Learn More

Our Science

Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.

View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing. A Pan-cancer Organoid Platform for Precision Medicine Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers. Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.

Improving patient care through high quality testing, clinical trial matching, and deep research data that powers scientific discovery

~65% of all Academic Medical Centers in the US are connected to Tempus
50%+ of oncologists in the US connected to Tempus through sequencing, clinical trial matching, and research-enabled partnerships
95% of the top 20 pharma oncology companies partner with Tempus
250+ biopharma partnerships
40,000,000+ de-identified research records to power scientific discovery to improve patient outcomes
40,000+ patients have been identified for potential enrollment into clinical trials in our network
350+ petabytes of data

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

Tempus has been selected by ARPA-H to provide testing and contract research organization (CRO) services in support of the agency’s ADAPT program, which aims to develop adaptive strategies that leverage biomarkers to target metastatic disease.

READ PRESS RELEASE

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

Tempus has received 510(k) clearance from the FDA for its RNA-based Tempus xR IVD device. xR IVD is available as a life sciences tool to support drug development programs.

READ PRESS RELEASE

Tempus Releases New Research Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer

A new study published in JCO Precision Oncology validates the clinical utility of the company’s PurIST® algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of PurIST into routine clinical care for patients with advanced PDAC, with the aim of informing first-line chemotherapy selection and improving patient outcomes.

READ PRESS RELEASE

This is AI-enabled precision medicine

This is the future of healthcare.

This site is protected by reCAPTCHA.